EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model

Yulan Qi, Ming Liang Chan, Diane R Mould, Kevin Larimore, Elena Fisheleva, Anu Cherukuri, Jonathan Day, Ravi Savarirayan, Melita Irving, Carlos A Bacino, Julie Hoover-Fong, Keiichi Ozono und 4 weitere

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01371-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Yulan Qi und 15 weiteren Autor:innen. Beteiligte Einrichtung: BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA, 949449, USA. yulan.qi@bmrn.com. Hauptthemen laut MEDLINE: Achondroplasia, Models, Biological, Body Weight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short stature, that has been shown to be well tolerated and effective in increasing linear growth. This study aimed to develop a population pharmacokinetic (PPK) model to characterize pharmacokinetics (PK) of vosoritide and establish a weight-band dosing regimen. METHODS: A PPK model was developed using data from five clinical trials in children with achondroplasia (aged 0.95-15 years) who received daily per-kg doses of vosoritide. The model was used to simulate expected exposures in children with a refined weight-band dosing regimen. Simulated exposure was compared with the observed exposure from the pivotal clinical trial to evaluate appropriateness of the weight-band dosing regimen. RESULTS: A one-compartment model with a change-point first-order absorption and first-order elimination accurately described PK of vosoritide in children with achondroplasia. Body weight was found to be a predictor of vosoritide's clearance and volume of distribution. Additionally, it was observed that dosing solution concentration and duration of treatment influenced bioavailability. The weight-band dosing regimen resulted in simulated exposures that were within the range demonstrated to be well tolerated and effective in the pivotal clinical trial and showed improved consistency in drug exposure across the achondroplasia population. CONCLUSIONS: The weight-band dosing regimen reduced the number of recommended dose levels by body weight and is expected to simplify dosing for children with achondroplasia and their caregivers. CLINICAL TRIAL REGISTRATION: NCT02055157, NCT02724228, NCT03197766, NCT03424018, and NCT03583697.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchondroplasiaModels, BiologicalBody WeightHumansChildAdolescentFemaleChild, PreschoolMaleInfantNatriuretic Peptide, C-TypeDose-Response Relationship, Drug

Substanzen

Natriuretic Peptide, C-Typevosoritide

Autor:innen und Institutionen

  • BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA, 949449, USA. yulan.qi@bmrn.com.
  • BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA, 949449, USA.
  • Projections Research Inc., Phoenixville, PA, USA.
  • BioMarin (UK) Limited, London, UK.
  • Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Parkville, VIC, Australia.
  • Guy's and St Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.

Förderung

  • BioMarin Pharmaceutical

Zitieren

APA

Qi, Y., Chan, M. L., Mould, D. R., Larimore, K., Fisheleva, E., Cherukuri, A., Day, J., Savarirayan, R., Irving, M., Bacino, C. A., Hoover-Fong, J., Ozono, K., Mohnike, K., Wilcox, W. R., Bober, M. B., & Henshaw, J. (2024). Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01371-6

Vancouver

Qi Y, Chan ML, Mould DR, Larimore K, Fisheleva E, Cherukuri A, et al. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01371-6

BibTeX
@article{Qi2024,
  author = {Qi, Yulan and Chan, Ming Liang and Mould, Diane R and Larimore, Kevin and Fisheleva, Elena and Cherukuri, Anu and Day, Jonathan and Savarirayan, Ravi and Irving, Melita and Bacino, Carlos A and Hoover-Fong, Julie and Ozono, Keiichi and Mohnike, Klaus and Wilcox, William R and Bober, Michael B and Henshaw, Joshua},
  title = {Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01371-6}
}
Kostenlos starten →